Can-Fite plans interim analysis advance in Phase III liver cancer study
Can-Fite said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma, after reporting overall survival longer than anticipated in the ongoing pivotal Phase III.
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinomaRamat Gan, Israel, Sept.
02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) TASE:CANF, a clinical-stage biotechnology company developing a pipeline of proprie…